An overview of HIV and chronic viral hepatitis co-infection

Digestive Diseases and Sciences

Volumn 53, Issue 4, 2008, Pages 899-904

  Cooper, Curtis L ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

HCV; HIV; Liver transplantation; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ENTECAVIR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ALCOHOL ABSTINENCE; ANEMIA; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; FEVER; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MIXED INFECTION; MONOTHERAPY; PANCREATITIS; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS;

ANTI-RETROVIRAL AGENTS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 40949114267     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0134-5     Document Type: Review

References (64)

1. Stubble L, Soriano V, Antunes F (1998) Hepatitis C in the EuroSIDA Cohort of European HIV-infected patients: prevalence and prognostic value. Abstract 22261. Presented at: 12th World AIDS Conference, Geneva
2. Thomas DL, Vlahov D, Solomon L et al (1995) Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 74:212-220
3. Strathdee SA, Patrick DM, Currie SL et al (1997) Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 11:F59-F65
4. Mehta SH, Cox A, Hoover DR et al (2002) Protection against persistence of hepatitis C. Lancet 359:1478-1483
5. Cribier B, Rey D, Schmitt C et al (1995) High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. Aids 9:1131-1136
6. Cribier B, Schmitt C, Rey D et al (1997) HIV increases hepatitis C viraemia irrespective of the hepatitis C virus genotype. Res Virol 148:267-271
7. Eyster ME, Fried MW, Di Bisceglie AM et al (1994) Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 84:1020-1023
8. Dragoni F, Cafolla A, Gentile G et al (1999) HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Haematologica 84:525-529
9. Lesens O, Deschenes M, Steben M et al (1999) Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 179:1254-1258
10. Benhamou Y, Bochet M, Di Martino V et al (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30:1054-1058
11. Kramer JR, Giordano TP, Souchek J et al (2005) The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 100:56-63
12. Santagostino E, Colombo M, Rivi M et al (2003) A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 102:78-82
13. Hadler SC, Judson FN, O'Malley PM et al (1991) Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 163:454-459
14. Colin JF, Cazals-Hatem D, Loriot MA et al (1999) Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29:1306-1310
15. Gilson RJ, Hawkins AE, Beecham MR et al (1997) Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 11:597-606
16. Greub G, Ledergerber B, Battegay M et al (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356:1800-1805
17. Sulkowski MS, Moore RD, Mehta SH et al (2002) Hepatitis C and progression of HIV disease. JAMA 288:199-206
18. Wiedmann M, Liebert UG, Oesen U et al (2000) Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 31:230-234
19. Keeffe EB, Iwarson S, McMahon BJ et al (1998) Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27:881-886
20. Wong EK, Bodsworth NJ, Slade MA et al (1996) Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 7:490-494
21. de Maat MM, Huitema AD, Mulder JW et al (2002) Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 54:378-85
22. Veronese L, Rautaureau J, Sadler BM et al (2000) Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 44:821-826
23. Khaliq Y, Gallicano K, Seguin I et al (2000) Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol 50:108-115
24. Arribas J, Pulido F, Peng J et al (2003) Evaluation of the multiple-dose pharmacokinetics of Lopinavir/Ritonavir (LPV/r) in HIV and HCV co-infected patients with mild to moderate hepatic insufficiency. Presentation F2/6. Presented at: 9th European AIDS Conference, Warsaw, Poland
25. John M, Flexman J, French MA (1998) Hepatitis C virus-associated hepatitis following treatment of HIV- infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 12:2289-2293
26. Cooper CL, Chen Y, Garber GE et al (2002) Perturbation of HCV RNA levels in plasma after suppressive HAART in HIV-HCV co-infected subjects. Abstract H-1736. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA
27. Neau D, Trimoulet P, Winnock M et al (2001) Impact of protease inhibitors on intrahepatic hepatitis C virus viral load. AIDS 15:1736-1738
28. Trimoulet P, Neau D, Le Bail B et al (2002) Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol 67:143-151
29. Torre D, Tambini R, Cadario F et al (2001) Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 33:1579-1585
30. Aceti A, Pasquazzi C, Zechini B (2003) Alanine aminotransferase decrease in HIV-hepatitis C virus co-infected patients responding to antiretroviral therapy. AIDS 17:2141-2142
31. Benhamou Y, Di Martino V, Bochet M et al (2001) Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34:283-287
32. Cooper C, LaRoche A, Kane M et al. (2003) Evaluation of the benefits of HAART in HIV-HCV co-infected subjects. Abstract H-826. Presented at: 43rd Interscience Conference on Antimicrobials and Chemotherapy, Chicago, IL
33. Aceti A, Pasquazzi C, Zechini B et al (2002) Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 29:41-48
34. Sulkowski MS, Thomas DL, Mehta SH et al (2002) Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35:182-189
35. Bernstein B, King M, Cernohous P et al (2001) Treatment of HIV + subjects co-infected with hepatitis B or C: week 60 safety and efficacy comparison of lopinavir/ritonavir vs. nelfinavir from a phase III blinded randomized clinical trial. Abstract P228. Presented at: 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens
36. Murphy RL, Brun S, Hicks C et al (2001) ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15:F1-F9
37. Walmsley S, Bernstein B, King M et al (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346:2039-2046
38. Fischl MA, Young B, Watkins M et al (2001) Direct study: a multicenter, open-label, 24-wk pilot study with a 24-wk extension to evaluate the safety, tolerability and efficacy of Indinavir-Ritonavir 800/100 bid in combination with d4T plus 3TC in HIV-infected individuals. Abstract I-1923. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL
39. Sulkowski MS, Thomas DL, Chaisson RE et al (2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283:74-80
40. Lazzarin A, Queiroz-Telles F, Frank I et al (2006) TMC114/r provides durable viral load suppression in treatment experience patients: Power 1 and 2 combined week 48 analysis. Presented at: XVI International AIDS Conference, Toronto, 2006TUAB0104
41. Hicks CB, Cahn P, Cooper DA et al (2006) Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomized open-label trials. Lancet 368:466-475
42. Cooper C, van Heeswijk RP, Bilodeau M et al (2005) The pharmacokinetics (PK) of single-dose and steady-state tipranavir/ritonavir (TPV/r) 500 mg/200 mg in subjects with mild and moderate hepatic impairment. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec City, Abstract #3-1
43. van Leth F, Phanuphak P, Ruxrungtham K et al (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363:1253-1263
44. Bourezane Y, Salard D, Hoen B et al (1998) DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 27:1321-1322
45. Gisolf EH, Dreezen C, Danner SA et al (2000) Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 31:1234-1239
46. Lafeuillade A, Hittinger G, Chadapaud S (2001) Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357:280-281
47. Salmon-Ceron D, Chauvelot-Moachon L, Abad S et al (2001) Mitochondrial toxic effects and ribavirin. Lancet 357:1803-1804
48. Fortgang IS, Belitsos PC, Chaisson RE et al (1995) Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 90:1433-1436
49. Lalezari JP, Eron JJ, Carlson M et al (2003) A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17:691-698
50. Lalezari JP, Henry K, O'Hearn M et al (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175-2185
51. Cooper CL, Parbhakar MA, Angel JB (2002) Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 34:1259-1263
52. Zylberberg H, Benhamou Y, Lagneaux JL et al (2000) Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 47:694-697
53. Neau D, Trimoulet P, Winnock M et al (2003) Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis 36:1564-1571
54. Landau A, Batisse D, Piketty C et al (2001) Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 15:2149-2155
55. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al (2004) Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351:438-450
56. Manns MP, McHutchison JG, Gordon SC et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965
57. Fried MW, Shiffman ML, Reddy KR et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982
58. Hammoud G, Li J, Vega K et al (2003) Poor tolerability to high Dose Peg Interferon and Ribavirin in HIV/HCV coinfected patients; initial results from a randomized multicenter trial. Abstract 347. Presented at: 54th Annual Meeting of the American Association for the Study of Liver Diseases, Boston
59. Bessesen M, Ives D, Condreay L et al (1999) Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28:1032-1035
60. Soriano V, Miro JM, Garcia-Samaniego J et al (2004) Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 11:2-17
61. Tabone M, Sidoli L, Laudi C et al (2002) Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 9:288-294
62. Cooper C, Cameron DW (2005) Effect of alcohol use on the impact of effective antiretroviral therapy for HIV co-infection on plasma HCV levels. Clin Infect Dis 41:S105-S109
63. Palella FJ Jr, Baker RK, Moorman AC et al (2006) Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43:27-34
64. Ragni MV, Belle SH, Im K et al (2003) Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 188:1412-1420